Reslizumab in the Treatment of Eosinophilic Granulomatosis With Polyangiitis (EGPA) Study

Swipe the table sideways for more columns.

Trial	Conditions	Status	Phase	Updated	More info	NCT ID
Reslizumab in the Treatment of Eosinophilic Granulomatosis With Polyangiitis (EGPA) Study	Hypersensitivity, Immediate, Respiratory Hypersensitivity, asthma, bronchial disorder, immune system disorder, lung disorder, obstructive lung disease, respiratory system disorder	Recruiting	Phase 2	2017-09-14		NCT02947945

2 results · Page 1 of 1

Swipe the table sideways for more columns.

Organizations	Linked trials
National Jewish Health	31
Teva Pharmaceuticals USA	6

1 results · Page 1 of 1

Swipe the table sideways for more columns.

Research sites	City	Country	Linked trials
National Jewish Health	Denver	United States	72

Clinical trials